Pacific Biosciences: Mark Van Oene, Peter Fromen
Pacific Biosciences announced it has appointed Mark Van Oene to the newly created role of chief operating officer and Peter Fromen as chief commercial officer (CCO), both effective Jan. 8, 2021.
Van Oene joins PacBio after 15 years at Illumina, where he most recently served as senior VP and CCO and oversaw worldwide sales and service. He will be responsible for managing PacBio's research, development, and manufacturing organizations and for driving strategic planning and corporate development activities.
Fromen also joins from Illumina, where he most recently served as global VP of population genomics and precision health. Based in London since 2015, he oversaw Illumina's partnership with Genomics England and the National Health System. Fromen will be responsible for all commercial activity worldwide, including sales, marketing, and customer support.
SomaLogic: Jason Cleveland, Angela Bakker Lee, Tracy Hervey, David McGovern
SomaLogic this week announced several new executive appointments.
Jason Cleveland will be the company's new chief technology officer. He joined SomaLogic in 2015 as a consultant and became a principal research fellow in 2018. Prior to SomaLogic, he was cofounder, chairman, and CEO of Asylum Research, a manufacturer of atomic force microscopes (AFM). He began his career at Digital Instruments, an early AFM maker. Cleveland has a PHD in physics from the Universiy of California, Santa Barbara and is a fellow of the American Physical Society.
SomaLogic has also appointed Angela Bakker Lee as its executive VP for healthcare markets, Tracy Hervey as executive VP for life science markets, and David McGovern as senior VP of marketing.
Prior to SomaLogic, Bakker Lee most recently served as chief strategy officer at Quid, an AI text analytics platform provider. Bakker Lee also previously led IBM's Global Business Services Healthcare for North America. Prior to IBM, Bakker Lee spent 15 years with ZS Associates, a management consulting firm specializing in commercial strategy and sales and marketing operations. Before ZS Associates, she worked at Molecular Applications Group.
Hervey most recently served as chief commercial officer at Amplity Health. Prior to Amplity Health, she served as VP of global accounts at Icon. Before Icon, Hervey held sales leadership roles at data science firm Iqvia and PPD, a global contract research organization.
McGovern previously served as strategic payer marketing lead at Pfizer. Prior to Pfizer, McGovern served as VP of marketing and business development at Change Healthcare. Before Change Healthcare, he held various leadership roles in global commercial development, marketing, and market access at Johnson & Johnson, Merck, and Otsuka. McGovern has also served as VP of marketing at Nupathe, which was later sold to Teva Pharmaceuticals.
Color: Claire Vo, Emily Reuter, Ashley Chandler
Color has added three individuals to its upper management in connection with a $167 million Series D financing announced this week. Claire Vo will be Color's new chief product officer, having previously held the same title at Optimizely. Emily Reuter is Color's new vice president of strategy and operations, joining the company from Uber, where she was head of investor relations. Ashley Chandler has been named Color's vice president of marketing, and joins the company from Stripe, where she led several marketing functions through a period of rapid growth.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.